SCHEMBL8917474

SCHEMBL8917474

OC(c1ccccc1)c1ccc2ncccc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 4/20 0.54
ALDH1A1 P00352 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 2/20 0.50
NPC1 O15118 2/20 0.50
POLB P06746 2/20 0.50
RAB9A P51151 1/20 0.50
MAPT P10636 2/20 0.47
KDM4E B2RXH2 1/20 0.47
TP53 P04637 1/20 0.47
HSP90AA1 P07900 1/20 0.47
HSP90AB1 P08238 1/20 0.47
TSHR P16473 1/20 0.47
CASP1 P29466 1/20 0.47
HTT P42858 1/20 0.47
ATM Q13315 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MCL1 Q07820 1/20 0.46
PABPC1 P11940 1/20 0.46
NR3C1 P04150 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31023643 0.93 NPC1 (0.57) METALDH1A1SMN1; SMN2LMNANPC1
SCHEMBL7097024 0.87 ALDH1A1 (0.51) METALDH1A1SMN1; SMN2LMNANPC1
SCHEMBL17035971 0.86 MET (0.43) METALDH1A1SMN1; SMN2LMNANPC1
SCHEMBL21709860 0.82 NPC1 (0.57) METALDH1A1SMN1; SMN2LMNANPC1
SCHEMBL6791174 0.81 KDM4A (0.48) METALDH1A1NPC1POLBRAB9A
SCHEMBL9192602 0.81 SMN1; SMN2 (0.47) METALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL188108 0.79 UGT2B7 (0.56) METALDH1A1SMN1; SMN2LMNANPC1
SCHEMBL30745165 0.79 UGT2B7 (0.56) METALDH1A1SMN1; SMN2LMNANPC1
SCHEMBL4065050 0.79 NPC1 (0.53) METALDH1A1SMN1; SMN2LMNANPC1
SCHEMBL29660594 0.79 SMN1; SMN2 (0.44) ALDH1A1SMN1; SMN2LMNAMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5612354-A CONTROLLING CELL GROWTH AND DIFFERENTIATION, RETINOIC ACID METABOLISM JANSSEN PHARMACEUTICA N.V. (BE) 1997-03-18 US disclosed
CN-1033752-C (1H-azol-1-ylmethyl) substituted quinoline or quinolinone derivatives JANSSEN PHARMACEUTICA NV (SE) 1997-01-08 CN disclosed
US-5441954-A Treatment of disorders characterized by increased proliferation and/or abnormal differentiation of cells JANSSEN PHARMACEUTICA N. V. (BE) 1995-08-15 US disclosed
CN-1106005-A A process for preparing (1H-azol-1-ylmethyl) substituted quinoxaline derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-08-02 CN disclosed
CN-1106004-A A process for preparing (1H-azol-1-ylmethyl) substituted quinazoline derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-08-02 CN disclosed
EP-0371564-B1 (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-07-12 EP disclosed
US-5268380-A Therapy for keratinization in mammals JANSSEN PHARMACEUTICA N.V. (BE) 1993-12-07 US disclosed
US-5185346-A Antiandrogenic agents; suppress elimination of retinoids; anticarcinogenic agents HANSSEN PHARMACEUTICA (BE) 1993-02-09 US disclosed
CN-1042912-A (1H-oxazol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA NV (BE) 1990-06-13 CN disclosed
EP-0371564-A2 (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1990-06-06 EP disclosed